This is Vol.73 Newsletter for March 2026.
In this issue, we cover the clinical, regulatory, and market environment continues to evolve rapidly. Key developments include the upcoming global biosimilar opportunity driven by major patent expirations, record-high clinical trial approvals in Korea, changing FDA policy on biosimilar development and 3-year exclusivity, the expansion of CAR-T into autoimmune diseases, rising global investment in Korea’s bio ecosystem, and new advances in stroke treatment devices.
